Adding arginine to chemo and immunotherapy for resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding an amino acid called arginine to standard chemotherapy and immunotherapy can help treat ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be able to care for yourself (fully active or restricted in physically strenuous activity but able to walk).
- Your cancer must be a specific type called high-grade serous or endometrioid.
- You must have recovered from side effects of previous treatments.
- Your blood counts, liver, and kidney function must be within acceptable levels.
- You must be willing to take daily arginine as an IV or oral supplement.
- You must not have a history of cold sores or genital herpes (HSV) outbreaks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
This trial tests a new immunotherapy drug (PD-1/CTLA-4 bispecific) combined with two chemotherapy drugs (nab-paclitaxel and carboplatin) given before surgery for advanced ovarian cancer. The goal is to shrink the tumor enough so it can be completely removed during surgery.
This trial tests if adding losartan, a blood pressure medicine, to the chemotherapy drug paclitaxel can help people with ovarian cancer that has stopped responding to platinum-based treatments. It is for those whose cancer has returned within 6 months of platinum therapy or did not respond at all.
This trial tests a new drug called JSKN003 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if this drug can shrink tumors or slow cancer growth. If you qualify, you may receive this experimental treatment and be closely monitored by a study team.
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.